Angiopoietins as Targets for Diabetic Retinopathy Treatment
Diabetic eye diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME) are among the leading causes of blindness in developed countries. Anti-VEGF therapies such as, ranibizumab, aflibercept and off-label bevacizumab have become first-line treatment for DME. While randomized contr...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2021
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/78191 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Angiopoietins as Targets for Diabetic Retinopathy Treatment
- Angiopoietin-1 for Myocardial Angiogenesis
- Prophylactic Medical Treatment of Diabetic Retinopathy
- Calcium Dobesilate in Prevention and Treatment of Diabetic Retinopathy
- Diabetic Retinopathy – An Update on Pathophysiology, Classification, Investigation and Treatment
- Diabetic Retinopathy
- Pathophysiology of Diabetic Retinopathy